Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Common Equity (2016 - 2025)

Guided Therapeutics' Common Equity history spans 16 years, with the latest figure at -$5.6 million for Q3 2025.

  • For Q3 2025, Common Equity fell 14.8% year-over-year to -$5.6 million; the TTM value through Sep 2025 reached -$5.6 million, down 14.8%, while the annual FY2024 figure was -$4.9 million, 28.46% down from the prior year.
  • Common Equity for Q3 2025 was -$5.6 million at Guided Therapeutics, down from -$5.5 million in the prior quarter.
  • Across five years, Common Equity topped out at -$2.7 million in Q3 2022 and bottomed at -$8.0 million in Q1 2021.
  • The 5-year median for Common Equity is -$4.9 million (2024), against an average of -$4.9 million.
  • The largest annual shift saw Common Equity soared 65.78% in 2022 before it plummeted 40.78% in 2024.
  • A 5-year view of Common Equity shows it stood at -$5.4 million in 2021, then skyrocketed by 47.05% to -$2.9 million in 2022, then tumbled by 32.02% to -$3.8 million in 2023, then decreased by 28.46% to -$4.9 million in 2024, then decreased by 15.48% to -$5.6 million in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Common Equity are -$5.6 million (Q3 2025), -$5.5 million (Q2 2025), and -$5.0 million (Q1 2025).